$CGTX

3 theses

bullish 100%neutral 0%bearish 0%

Avg return (3m)

-26.9%

Win rate (3m)

0% (3 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Nov 2, 4:15 PM ET

$CGTXr/pennystocksStock Infobullish

u/Asleep-Procedure-131 · 151d agono track record yet

Long 36,300 shares of CGTX

How come no one is talking about CGTX?

CGTX announced phase 3 trial data with multiple near-term catalysts lined up in June, including the H.C. Wainwright Summit, Annual Shareholder Meeting, and FDA Written Minutes on June 19-20, which the author identifies as the primary catalyst. The phase 3 design is public and 3,000 institutional investors have been briefed, positioning the stock for potential upside as these catalysts approach.

At post $1.36Now $0.71-47.8% since postedas of Nov 2, 4:15 PM ET

1d-5.1%

3d-5.1%

1w-11.8%

1m-14.0%

3m-22.8%

6m—

1y—

original post →

$CGTXr/pennystocksDDbullish

u/footballman25 · 416d agono track record yet

Long CGTX

$CGTX the newest update— I am pounding the table

The author believes CGTX's stock has been oversold due to unfounded BTD denial rumors. With positive Phase 2 data showing pTau reversals, a fresh $30M capital raise securing Phase 3 runway, and a potential BTD approval catalyst in an unmet LBD market, the stock at $2 range offers a compelling buying opportunity before upcoming catalysts materialize.

At post $2.17Now $0.71-67.3% since postedas of Nov 2, 4:15 PM ET

1d—

3d-29.0%

1w-35.5%

1m-15.7%

3m-25.3%

6m-47.5%

1y-54.7%

original post →

$CGTXr/pennystocksStock Infobullish

u/oquido · 423d ago1 prior · awaiting results

“I hold a long position”

$CGTX, Upcoming Plans - Comprehensive Discussion with the IR Representative

Cognition Therapeutics is positioned for strong Phase 3 progression with successful FDA alignment for a dual six-month Alzheimer's trial design and promising DLB data showing high potential for zervimesine (CT1812). Recent capital raises and delisting risk resolution enable active partnership discussions with Tier 1 pharmas in the near term.

At post $2.61Now $0.71-72.8% since postedas of Nov 2, 4:15 PM ET

1d—

3d-8.0%

1w-16.9%

1m-40.6%

3m-32.6%

6m-59.4%

1y-60.5%

original post →

End of results.